Alloy Therapeutics Partners with the University of British Columbia
Alloy Therapeutics Inc. has partnered with the University of British Columbia (UBC) to accelerate the discovery of novel antibody therapeutics aimed at strengthening pandemic preparedness. Through this collaboration, Alloy will contribute its expertise in antibody discovery to support UBC’s efforts under the PROGENITER program—part of Canada’s Immuno-Engineering and Biomanufacturing Hub (CIEBH). UBC researchers will use advanced high-throughput cryo-electron microscopy to develop next-generation antibody therapies targeting infectious diseases, helping Canada prepare for future health threats.
Alloy Therapeutics Partners with the University of British Columbia